Comparative study of automated plateletpheresis using five different apheresis systems in a tertiary care hospital

Quantity, quality, and functionality of peripheral blood cells derived from residual blood of different apheresis kits

“…Research with human material such as PBMCs and immune cells strongly depends on the availability of PBMC sources, which can be a limiting factor, especially if large quantities are required. Whole blood, WBC depletion filters, buffy coats, and LRSCs from the Trima Accel plateletpheresis device are commonly used starting material for PBMC isolation and further usage of different subpopulations . The PBMC source for research purposes is mostly determined by the local blood donation service based on the blood collection systems established in their daily routine.…”

“…Whole blood, WBC depletion filters, buffy coats, and LRSCs from the Trima Accel plateletpheresis device are commonly used starting material for PBMC isolation and further usage of different subpopulations. 2,[8][9][10][12][13][14][15]24,25 The PBMC source for research purposes is mostly determined by the local blood donation service based on the blood collection systems established in their daily routine. In this study, we evaluated quantity and quality of PBMCs isolated from apheresis kits of the AMICUS and Trima Accel preparative hemapheresis devices, the latter having been our standard source for many years.…”

“…Peripheral blood, buffy coats, or WBC removal filters are common sources for PBMCs after isolation by density gradient centrifugation, but may not always be available in sufficient quantities . To date, there are different apheresis platforms on the market using intermittent flow or continuous flow . Dependent on the local blood donation service, alternative sources for PBMC isolation may be more readily available.…”

Improvement of plateletpheresis via technical modification on the MCS+

“…This study focused mainly on the time‐dependent variable to assess the effect of relevant technical parameter modification on MCS+. One study reported that MCS+ was the slowest when comparing with other devices including Amicus, Fresenius and CS 3000 in terms of donation time and PT (Chaudhary et al , ). Another report by Bueno et al also showed the same results: MCS+ spent the most time to produce the same and standard platelet dose compared with the Accel and Amicus (Bueno et al , ).…”

Feasibility and safety of triple dose platelet collection by apheresis

“…Our eligibility criterion for the body weight was lower than in the Austrian/German multicenter study (>80 kg) [8] but showed to be safe to avoid a higher rate of side effects. As a donor pool of triple platelet donors is limited, donors not fulfilling the aforementioned criteria can [14][15][16]. This may be due to the fact that almost two-thirds of our donors were male and routine prophylactic calcium supplementation before apheresis which has been recommended by many authors and has been implemented at our center [14,15].…”